PharmSource Report Analyzes Dose CMO Growth

According to a recent report published by PharmSource Information Services, growth of the pharma/biopharma contract manufacturing sector is likely to continue to slow relative to overall industry growth despite the significant increase in New Active Substances launched from 2014 onwards. Key reasons for the slowing industry growth rate, according to the report, are the appreciation of the U.S. dollar against the Euro, client losses and regulatory compliance issues.
 
The new report, Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook–2016 Edition, provides comprehensive analysis of the performance of the dose CMO business. The analysis is derived from PharmSource’s database of global contract manufacturers. Insights detailed in the report include:
 
•  The contract dose manufacturing industry generated revenues of $18.5 billion in 2015.

•  Acquisitions of facilities from pharma/biopharma companies were responsible for a significant share of industry growth.

•  Consolidation remained a feature of the sector in 2015 with eight CMO acquisitions.

•  Going forward, CMO industry growth will be challenged by global bio/pharma companies declining propensity to outsource new approvals, along with shrinking unit volume per product, too much capacity relative to market size and declining prices.
 
The information in this report aims to help CMOs and their investors make informed critical strategic decisions, as well as assess current CMO networks and develop long-term sourcing strategies.
 
PharmSource is an unbiased authority of knowledge about the global pharma/biopharma contract services industry. The company’s publications, database platforms, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities.